Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission

Table 1

Demographic and clinical data at baseline of per treatment group.

	IFX	EEN	value
	23	35
Age (yr)	(7.33-15.25)	(7.67-15.58)	0.16
Males/females	21/2	22/13	0.01
Height (cm)			0.50
Weight (kg)			0.77
HFA -score			0.43
BMIFA -score			0.92
PCDAI score			0.09
CDEIS score			0.70
Disease location, (%)			0.43
L1	8	8.2
L2	0	1.4
L3	32	41.1
L4a	26	13.7
L4b	34	35.6
Disease behavior, (%)			0.24
B1	84.21	94.29
B2	15.79	5.71
Perianal disease, (%)	56.52	8.57	<0.01
Disease growth, (%)			0.85
G0	86.96	88.57
G1	13.04	11.43
Alb (g/L)			0.43
ESR (mm/h)			0.66
CRP (mg/L), normal (%)	43.48	22.86	0.10

IFX: infliximab; EEN: exclusive enteral nutrition; PCDAI: pediatric Crohn’s disease activity index; CDEIS: Crohn’s disease endoscopic index of severity; BMIFA: body mass index for age; HFA: height for age; Alb: albumin; ESR: erythrocyte sedimentation rate; CRP: C reactive protein.